Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor

Table 1 Clinical characteristics of patients according to tumoral CCR7 expression

Characteristics	Patients		Tumoral CCR7 expression
Characteristics	n	%	low	high	P-value
No. of patients	110	100	53	57
Age, years, mean (SD)	57.5 (11.9)
Men	79	71.8
ECOG PS					0.198^c
0	81	73.6	42	39
1	29	26.4	11	18
Prior nephrectomy					N/A
Yes	110	100.0
No	0	0.0
Histology					0.086^c
Clear cell	88	80.0	46	42
Non-clear cell type	22	20.0	7	15
Papillary	15	13.6
Chromophobe	2	1.8
Collecting duct	2	1.8
Unclassified	3	2.7
Fuhrman grade (7 excluded)					0.147^d
1	2	1.8	2	0
2	53	48.2	28	25
3	41	37.3	18	23
4	7	6.4	5	2
TNM stage at initial diagnosis					0.004 ^c
I-III	51	46.4	32	19
IV	59	53.6	21	38
Site of metastatic disease^a
Lung	82	74.5
Liver	13	11.8
Bone	18	16.4
Lymph node	29	26.4
Adrenal gland	8	7.3
Brain and others	15	13.6
Lymph node involvement^a					0.031 ^c
No	81	73.6	44	37
Yes	29	26.4	9	20
No. of metastatic sites^a					0.070^c
1	76	69.1	41	35
≥ 2	34	30.9	12	22
Tyrosine kinase inhibitors					0.254^c
Sunitinib	73	66.4	38	35
Sorafenib	37	33.6	15	22
Heng’s risk group					0.271^d
Favorable	22	20	12	10
Intermediate	60	54.5	30	30
Poor	28	25.5	11	17
Best response (3 not assessable)					<0.001 ^d
Partial response	27	25.2	18	9
Stable disease for ≥3 months	57	53.3	30	27
Progressive disease^b	23	21.5	2	21

Bold data means statistical significant (P<0.05)
SD standard deviation, ECOG PS Eastern Cooperative Oncology Group performance status
P-value < 0.05 was regarded as statistically significant
^aAt the time initializing tyrosine kinase inhibitors
^bIncluding stable disease for <3 months
^cχ² test or Fisher’s exact test
^dCochran-Mantel-Haenszel χ ² test

ISSN: 1471-2407